Literature DB >> 31493743

Design, synthesis and biological evaluation of a new series of thiazolyl-pyrazolines as dual EGFR and HER2 inhibitors.

Belgin Sever1, Mehlika Dilek Altıntop2, Mohamed O Radwan3, Ahmet Özdemir1, Masami Otsuka4, Mikako Fujita5, Halil I Ciftci6.   

Abstract

Epidermal growth factor receptor (EGFR, also known as HER1) and HER2, prominent members of receptor tyrosine kinase (RTK) superfamily, have been reported as diagnostic or prognostic markers in tumor progression. Based on the importance of molecular hybridization of pyrazoline and thiazole scaffolds in the discovery of potent anticancer agents, new thiazolyl-pyrazoline derivatives (3a-v) were synthesized and screened for their cytotoxic effects on A549 human lung adenocarcinoma, MCF-7 human breast adenocarcinoma and A375 human melanoma cell lines. 1-(4-(4-Fluorophenyl)thiazol-2-yl)-3-(4-morpholinophenyl)-5-(4-chlorophenyl)-2-pyrazoline (3c),1-(4-(4-cyanophenyl)thiazol-2-yl)-3-(4-morpholinophenyl)-5-(4-chlorophenyl)-2-pyrazoline (3f) and 1-(4-(4-cyanophenyl)thiazol-2-yl)-3-(4-piperidinophenyl)-5-(4-chlorophenyl)-2-pyrazoline (3q) were found as the most potent anticancer agents against A549 and MCF-7 cell lines compared to erlotinib. Compound 3q also showed moderate cytotoxic activity against A375 cell line. Moreover, these compounds exert a cancer cell-selective action against Jurkat cell line posing no toxicity on peripheral blood mononuclear cells (PBMCs). In order to enlighten the mechanism of action underlying anticancer activity, compounds 3c, 3f and 3q were investigated for their apoptotic effects on A549 and MCF-7 cell lines and inhibitory potencies against eight different RTKs including EGFR and HER2 compared to erlotinib. The results indicated that compounds 3f and 3q induced apoptosis in both cell lines and showed significant EGFR inhibitory activity with IC50 values of 4.34 ± 0.66 μM and 4.71 ± 0.84 μM, respectively when compared with erlotinib (IC50 = 0.05 ± 0.01 μM). Besides, compound 3f also inhibited HER2 notably with an IC50 value of 2.28 ± 0.53 μM making it a dual EGFR and HER2 inhibitor. Molecular docking studies, which were conducted to support the in vitro assays, pointed out that compound 3f showed high affinity into the ATP binding sites of EGFR and HER2.
Copyright © 2019 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Apoptosis; Cancer; EGFR; HER2; Molecular docking; Thiazolyl-pyrazoline

Mesh:

Substances:

Year:  2019        PMID: 31493743     DOI: 10.1016/j.ejmech.2019.111648

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  10 in total

1.  Anticancer activity of Turkish marine extracts: a purple sponge extract induces apoptosis with multitarget kinase inhibition activity.

Authors:  Halil I Ciftci; Mustafa Can; Doha E Ellakwa; Salih C Suner; Mohamed A Ibrahim; Ayhan Oral; Nazim Sekeroglu; Barış Özalp; Masami Otsuka; Mikako Fujita; Mustafa Alparslan; Mohamed O Radwan
Journal:  Invest New Drugs       Date:  2020-02-15       Impact factor: 3.850

2.  Design and Synthesis of Carbothioamide/Carboxamide-Based Pyrazoline Analogs as Potential Anticancer Agents: Apoptosis, Molecular Docking, ADME Assay, and DNA Binding Studies.

Authors:  Manish Rana; Md Imam Faizan; Sajad Hussain Dar; Tanveer Ahmad
Journal:  ACS Omega       Date:  2022-06-23

3.  Novel 2-(5-Aryl-4,5-Dihydropyrazol-1-yl)thiazol-4-One as EGFR Inhibitors: Synthesis, Biological Assessment and Molecular Docking Insights.

Authors:  Tarfah Al-Warhi; Ahmed M El Kerdawy; Mohamed A Said; Amgad Albohy; Zainab M Elsayed; Nada Aljaeed; Eslam B Elkaeed; Wagdy M Eldehna; Hatem A Abdel-Aziz; Miral A Abdelmoaz
Journal:  Drug Des Devel Ther       Date:  2022-05-16       Impact factor: 4.319

4.  Discovery of Anilino-1,4-naphthoquinones as Potent EGFR Tyrosine Kinase Inhibitors: Synthesis, Biological Evaluation, and Comprehensive Molecular Modeling.

Authors:  Panupong Mahalapbutr; Ronnakorn Leechaisit; Anusit Thongnum; Duangjai Todsaporn; Veda Prachayasittikul; Thanyada Rungrotmongkol; Supaluk Prachayasittikul; Somsak Ruchirawat; Virapong Prachayasittikul; Ratchanok Pingaew
Journal:  ACS Omega       Date:  2022-05-18

5.  Design, Synthesis and Biological Evaluation of Pentacyclic Triterpene Derivatives: Optimization of Anti-ABL Kinase Activity.

Authors:  Halil I Ciftci; Mohamed O Radwan; Safiye E Ozturk; N Gokce Ulusoy; Ece Sozer; Doha E Ellakwa; Zeynep Ocak; Mustafa Can; Taha F S Ali; Howaida I Abd-Alla; Nurettin Yayli; Hiroshi Tateishi; Masami Otsuka; Mikako Fujita
Journal:  Molecules       Date:  2019-09-30       Impact factor: 4.411

6.  In Vitro and In Silico Evaluation of Anticancer Activity of New Indole-Based 1,3,4-Oxadiazoles as EGFR and COX-2 Inhibitors.

Authors:  Belgin Sever; Mehlika Dilek Altıntop; Ahmet Özdemir; Gülşen Akalın Çiftçi; Doha E Ellakwa; Hiroshi Tateishi; Mohamed O Radwan; Mahmoud A A Ibrahim; Masami Otsuka; Mikako Fujita; Halil I Ciftci; Taha F S Ali
Journal:  Molecules       Date:  2020-11-07       Impact factor: 4.411

7.  Effects of dacomitinib on the pharmacokinetics of poziotinib in vivo and in vitro.

Authors:  Weiping Ji; Jiquan Shen; Bo Wang; Feifei Chen; Deru Meng; Shuanghu Wang; Dapeng Dai; Yunfang Zhou; Changxiong Wang; Quan Zhou
Journal:  Pharm Biol       Date:  2021-12       Impact factor: 3.503

8.  Synthesis, biological evaluation, and in silico studies of novel chalcone- and pyrazoline-based 1,3,5-triazines as potential anticancer agents.

Authors:  Leydi M Moreno; Jairo Quiroga; Rodrigo Abonia; Antonino Lauria; Annamaria Martorana; Henry Insuasty; Braulio Insuasty
Journal:  RSC Adv       Date:  2020-09-15       Impact factor: 4.036

9.  A Potent EGFR Inhibitor, N-Phenyl Pyrazoline Derivative Suppresses Aggressiveness and Cancer Stem Cell-Like Phenotype of Cervical Cancer Cells.

Authors:  Pamungkas Bagus Satriyo; Artania Adnin Tri Suma; Stephanus Satria Wira Waskitha; Tutik Dwi Wahyuningsih; Eti Nurwening Sholikhah
Journal:  Drug Des Devel Ther       Date:  2022-07-20       Impact factor: 4.319

Review 10.  Pyrazoline Hybrids as Promising Anticancer Agents: An Up-to-Date Overview.

Authors:  Dimitris Matiadis; Marina Sagnou
Journal:  Int J Mol Sci       Date:  2020-07-31       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.